NEW YORK (GenomeWeb) – Asuragen today announced it has received a clinical laboratory permit from New York state to offer the company's Xpansion Interpreter and miRInform Thyroid tests in the state.

The Austin, Texas-based firm can now offer the tests in all 50 states in the US, it said.

Xpansion Interpreter is a reflex test for fragile X carriers. It determines the total number of CGG repeats and number of AGG interruptions in the Fragile X Mental Retardation gene and can help determine the risk for potential parents of having a child with fragile X syndrome.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.